Factor VIIa binding and internalization in hepatocytes

G Hjortoe

B Sorensen

L Petersen

L Rao

^{Health Care Discovery, Novo Nordisk, Maalov, Denmark; and}

^{Biomedical Research, The University of Texas Health Center at Tyler, Tyler, TX, USA}

Correspondence: L. Vijaya Mohan Rao, Biomedical Research, The University of Texas Health Center at Tyler, 11937 US highway 271, Tyler, TX 75708, Ph: 903-877-7332, Fax: 903-877-7426, e-mail: ude.tchtu@oar.yajiv

Summary

The liver is believed to be the primary clearance organ for coagulation proteases, including factor VIIa. However, at present, clearance mechanisms for FVIIa in liver are unknown. To obtain information on the FVIIa clearance mechanism, we investigated the binding and internalization of FVIIa in liver cells using a human hepatoma cell line (HEPG2), and primary rat and human hepatocytes as cell models. ^{I-FVIIa bound to HEPG2 cells in a time-and dose- dependent manner. Anti-tissue factor antibodies reduced the binding by about 25%, whereas 50-fold molar excess of unlabeled FVIIa had no effect. HEPG2 cells internalized FVIIa with a rate of 10 fmoles/10}^{cells/h. In contrast to HEPG2 cells, FVIIa binding to primary rat hepatocytes was completely independent of TF, and excess unlabeled FVIIa partly reduced the binding of}^{I-FVIIa to rat hepatocytes. Further, compared to HEPG2 cells, 3 to 4- fold more FVIIa bound to rat primary hepatocytes, and the bound FVIIa was internalized at a faster rate. Similar FVIIa binding and internalization profiles were observed in primary human hepatocytes. Plasma inhibitors had no effect on FVIIa binding and internalization in hepatocytes. In contrast, annexin V, which binds to phosphatidylserine, blocked the binding and internalization. Consistent with this, binding of gla-domain-deleted FVIIa to hepatocytes was markedly diminished. In summary, the data presented herein reveal differences between HEPG2 cells and primary liver cells in FVIIa binding and internalization, and suggest that the rapid turnover of membrane and not a receptor-mediated endocytosis may be responsible for internalization of FVII/FVIIa in primary hepatocytes.}

Keywords: factor VIIa, hepatocytes, liver, internalization

Summary

References

1. Hasselback R, Hjort PFEffect of heparin on in vivo turnover of clotting factor. J Appl Physiol. 1960;15:945–48.[PubMed][Google Scholar]
2. O’Reilly RA, Aggeler PM, Leong LSStudies on the coumarin anticoagulation drugs: The pharmacodynamics of warfarin in man. J Clin Invest. 1963;42:1542–51.[Google Scholar]
3. Bjorkman S, Berntorp EPharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001;40:815–32.[PubMed][Google Scholar]
4. Loeliger EA, van der Esch B, ter Haar Romney-Wachter CC, Booij HLFactor VII; its turnover rate and its possible role in thrombogenesis. Thromb Diath Haemorrh. 1960;4:196–200.[PubMed][Google Scholar]
5. Fair DSQuantitation of Factor VII in the Plasma of Normal and Warfarin-Treated Individuals by Radioimmunoassay. Blood. 1983;62:784–91.[PubMed][Google Scholar]
6. Fuchs HE, Pizzo SVRegulation of Factor Xa In Vitro in Human and Mouse Plasma and In Vivo in Mouse. J Clin Invest N Y. 1983;72:2041–49.[Google Scholar]
7. Fuchs HE, Trapp HG, Griffith MJ, Roberts HR, Pizzo SV. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors. J Clin Invest. 1984;73:1696–703.
8. Seligsohn U, Kasper CK, Osterud B, Rapaport SIActivated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. Blood. 1979;53:828–37.[PubMed][Google Scholar]
9. Erhardtsen EPharmacokinetics of recombinant activated factor VII (rFVIIa) Semin Thromb Hemost. 2000;26:385–91.[PubMed][Google Scholar]
10. Iakhiaev A, Pendurthi UR, Voigt J, Ezban M, Rao LVMCatabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor. J Biol Chem. 1999;274:36995–7003.[PubMed][Google Scholar]
11. Fleck RA, Rao LVM, Rapaport SI, Varki NLocalization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res. 1990;59:421–37.[PubMed][Google Scholar]
12. Drake TA, Morrissey JH, Edgington TSSelective cellular expression of tissue factor in human tissues: Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989;134:1087–97.[Google Scholar]
13. Chang GTG, Kisiel WInternalization and degradation of recombinant human coagulation factor VIIa in the human hepatoma cell line HuH7. Thromb Haemost. 1995;73:231–38.[PubMed][Google Scholar]
14. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato JGrowth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 1982;42:3858–63.[PubMed][Google Scholar]
15. Biessen EA, Noorman F, van Teijlingen ME, et al Lysine-based cluster mannosides that inhibit ligand binding to the human mannose receptor at nanomolar concentration. J Biol Chem. 1996;271:28024–30.[PubMed][Google Scholar]
16. Bajaj SP, Rapaport SI, Prodanos CA simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem. 1981;11:397–412.[PubMed][Google Scholar]
17. Rao LVMCharacterization of anti-tissue factor antibody and its use in immunoaffinity purification of human tissue factor. Thromb Res. 1988;51:373–84.[PubMed][Google Scholar]
18. Seglen POPreparation of isolated rat liver cells. Methods Cell Biol. 1976;13:29–83.[PubMed][Google Scholar]
19. Le DT, Rapaport SI, Rao LVMRelations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. J Biol Chem. 1992;267:15447–54.[PubMed][Google Scholar]
20. Iakhiaev A, Pendurthi UR, Rao LVMActive site blockade of factor VIIa alters its intracellular distribution. J Biol Chem. 2001;276:45895–901.[PubMed][Google Scholar]
21. Tait JF, Gibson D, Fujikawa KPhospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem. 1989;264:7944–49.[PubMed][Google Scholar]
22. Schwartz ALThe hepatic asialoglycoprotein receptor. CRC Crit Rev Biochem. 1984;16:207–33.[PubMed][Google Scholar]
23. Beeby TL, Chasseaud LF, Taylor T, Thomsen MKDistribution of the recombinant coagulation factor 125I-rFVIIa in rats. Thromb Haemost. 1993;70:465–68.[PubMed][Google Scholar]
24. Thomsen MK, Diness V, Nilsson P, Rasmussen SN, Taylor T, Hedner UPharmacokinetics of recombinant factor VIIa in the rat--a comparison of bio-, immuno- and isotope assays. Thromb Haemost. 1993;70:458–64.[PubMed][Google Scholar]
25. Deykin DThe role of the liver in serum-induced hypercoagulability. J Clin Invest. 1966;45:256–63.[Google Scholar]
26. Meijer DK, Scholtens HB, Hardonk MJThe role of the liver in clearance of glycoproteins from the general circulation, with special reference to intestinal alkaline phosphatase. Pharm Weekbl Sci. 1982;4:57–70.[PubMed][Google Scholar]
27. Kelly DA, Summerfield JAHemostasis in liver disease. Semin Liver Dis. 1987;7:182–91.[PubMed][Google Scholar]
28. Rao LVM, Rapaport SI, Hoang ADBinding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood. 1993;81:2600–2607.[PubMed][Google Scholar]
29. Broze GJ, Jr, Girard TJ, Novotny WFRegulation of coagulation by a multivalent Kunitz-type inhibitor. Biochem. 1990;29:7539–45.[PubMed][Google Scholar]
30. Scharschmidt BF, Lake JR, Renner EL, Licko V, Van Dyke RWFluid phase endocytosis by cultured rat hepatocytes and perfused rat liver: implications for plasma membrane turnover and vesicular trafficking of fluid phase markers. Proc Natl Acad Sci U S A. 1986;83:9488–92.[Google Scholar]
31. McDonald JF, Shah AM, Schwalbe RA, Kisiel W, Dahlback B, Nelsestuen GLComparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. Biochem. 1997;36:5120–5127.[PubMed][Google Scholar]